Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) had its target price lowered by TD Securities from C$2.00 to C$1.50 in a report released on Wednesday morning, BayStreet.CA reports. TD Securities currently has a hold rating on the stock.
Separately, Bloom Burton reiterated a hold rating on shares of Cipher Pharmaceuticals in a research report on Monday.
CPH stock traded down C$0.06 during trading hours on Wednesday, hitting C$1.14. 57,170 shares of the stock were exchanged, compared to its average volume of 32,115. The company has a debt-to-equity ratio of 62.34, a current ratio of 1.06 and a quick ratio of 0.98. The firm has a market cap of $33.10 million and a price-to-earnings ratio of 17.01. The firm has a 50-day moving average price of C$1.23. Cipher Pharmaceuticals has a 12 month low of C$1.11 and a 12 month high of C$3.66.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain; and Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients.
Recommended Story: FAANG Stocks
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.